Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

Share

Full Title

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

Purpose

The purpose of this study is to test a mobile app intervention called iThrive to help survivors of breast cancer and rare cancers cope with the fear of recurrence. iThrive is designed to help patients reduce their fear of recurrence through the repeated practice of tasks designed to help shift mental habits that may be linked to increased anxiety.

Participants in this study will be randomly assigned to use iThrive and a symptom tracking app, or a symptom tracking app alone for a 4-week period. Those assigned to iThrive will be asked to complete 8 or 16 sessions using the app. In addition, participants will complete questionnaires at the start of the study, after completing the intervention, and three months later to evaluate the apps.

View the Privacy Policy for this app

Eligibility

This study will include people age 18 and older who have completed active treatment for a stage I-III rare cancer and/or breast cancer. Eligible rare cancer diagnoses include rare melanoma subtypes (acral, uveal, mucosal), Kaposi sarcoma, Merkle cell carcinoma, sebaceous cell carcinoma, rare gynecological cancers (vaginal, vulvar, ovarian, uterine, fallopian tube), and pediatric cancers. People with other rare cancer diagnoses may be eligible. All participants must have access to an iOS device (iPhone or iPad). Learn if you are eligible to participate in this study.

For more information, please contact the research staff at [email protected] or 646-608-8330, or contact Dr. Wendy Lichtenthal at 646-608-8204.

Protocol

11-204

Phase

Pilot

Investigator

Co-Investigators